ALS Limited (ASX:ALQ): Laboratory Testing Earnings and Expansion Plans

Aditi Sarkar

20 October 2026 09:34 PM AEDT

ALS Limited (ASX:ALQ): Laboratory Testing Earnings and Expansion Plans

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

ALS Limited (ASX:ALQ) reported FY26 revenue of AUD 3.32 billion, up 10.7%.
Underlying EBIT reached AUD 599.0 million; statutory net profit was AUD 318.7 million.
Commodities revenue rose 18.8%, while Life Sciences revenue increased 6.0%.
The company outlined approximately AUD 230 million of laboratory hub investments.

ALS Limited provides laboratory testing and analytical services for mining, environmental, food, pharmaceutical and industrial customers across international markets. The company has reported its financial results for the year ended 31 March 2026 and outlined investment in testing capacity and laboratory systems. ALS Limited (ASX:ALQ) closed at AUD 20.07 on 20 October 2026, down 0.59% for the day. Its latest annual figures show differing conditions across Commodities and Life Sciences, alongside continued expenditure on new laboratory facilities.

Company Business

ALS operates through two reporting divisions: Commodities and Life Sciences. Commodities includes geochemistry, metallurgy, mine-site laboratory work, coal testing, assay and inspection, and oil analysis. Demand in those activities depends partly on exploration activity, mine production and industrial testing requirements.

Life Sciences encompasses environmental monitoring, food safety and pharmaceutical services. Its customers use laboratory results to assess materials, products and compliance with technical standards. ALS Limited (ASX:ALQ) serves markets in Asia-Pacific, Europe, the Americas and other regions, meaning business conditions and currency movements vary across its operations.

Recent Development

In May 2026, the company released its FY26 results and described plans for four major laboratory hubs. The projects comprise a minerals facility in Lima and environmental facilities in Sydney, Bangkok and Prague. The total program was estimated at approximately AUD 230 million, including AUD 93.7 million of spending during FY26.

The company indicated that the Lima and Sydney laboratories were expected to be commissioned in the second half of FY27. ALS Limited (ASX:ALQ) also reported progress in laboratory automation, digital infrastructure and artificial-intelligence applications. Those initiatives remain execution programs rather than realised financial benefits at the October reporting date.

Financial Performance and Sector Context

For FY26, ALS recorded revenue of AUD 3,320.1 million, an increase of 10.7% against FY25. Underlying EBIT grew 19.3% to AUD 599.0 million, with a margin of 18.0%. Underlying net profit after tax was AUD 381.2 million, while statutory net profit reached AUD 318.7 million. These are different earnings measures and should not be treated interchangeably.

Commodities generated AUD 1,294.2 million in revenue, up 18.8%, and underlying EBIT of AUD 381.5 million. Minerals sample volumes, exploration activity and pricing supported that division. Life Sciences revenue increased 6.0% to AUD 2,025.9 million, with underlying EBIT of AUD 296.5 million. Food testing recorded 7.2% organic growth, whereas pharmaceutical organic revenue declined 1.6%.

Environmental testing experienced weaker conditions in the Americas, including project deferrals and integration issues, while Asia-Pacific and European activities grew. This divergence matters because ALS Limited (ASX:ALQ) has exposure both to mineral exploration spending and more recurring testing associated with food, environmental and regulatory requirements.

Free cash flow was AUD 674.1 million in FY26, and reported net debt was AUD 1,069.5 million at 31 March 2026. The company declared a 23.1-cent final dividend, bringing the full-year dividend to 42.5 cents per share. Financial leverage stood at 1.5 times, below the company’s stated target range of 1.7–2.3 times.

Risks to Consider

Exposure to minerals exploration creates sensitivity to customers’ commodity budgets and project schedules. Laboratory expansion carries commissioning, construction and staffing risks. Integration issues in Environmental operations and uneven pharmaceutical demand could affect efficiency and margins. Overseas earnings introduce foreign-exchange exposure, while evolving testing regulations can alter demand or service requirements. ALS Limited (ASX:ALQ) also faces execution risk in achieving benefits from automation and recently acquired businesses.

What to Watch Next

The next scheduled half-year result, covering the period ended 30 September 2026, is listed by the company for November 2026. Relevant measures include organic growth and margins in Minerals, Environmental performance in the Americas, and cash conversion. The timing and cost of laboratory hub commissioning also warrant monitoring.

For FY27, management targeted mid-to-high single-digit group organic revenue growth and further margin expansion. It also outlined an expectation for 13–15% Minerals organic revenue growth. These are company targets, not achieved results. Any subsequent changes to guidance should be assessed against published operational and financial updates from ALS Limited (ASX:ALQ).

Key Insights

ALS delivered higher FY26 revenue and earnings, supported particularly by Commodities testing. Life Sciences expanded more moderately, reflecting different trading conditions across Food, Environmental and Pharma. Cash generation and reduced net debt provide context for the company's capacity expenditure, but completion costs and operating outcomes remain to be observed. For ALS Limited (ASX:ALQ), upcoming reporting will clarify whether divisional margins and laboratory investments are progressing against the company's stated plans.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.